| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 1e-05 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.13 | 4e-05 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.22 | 4e-05 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-05 |